Topline results were announced from a phase 3 trial evaluating the safety, tolerability, and immunogenicity of Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine.

Semaglutide was associated with a significantly greater reduction in MACE risk vs tirzepatide in patients with overweight/obesity and CVD.

For patients with acute myocardial infarction (MI), beta-blockers are not beneficial in those without reduced left ventricular ejection fraction (LVEF).

Reducing thrombolysis-to-puncture time improves outcomes in patients with AIS caused by LVO receiving IVT followed by EVT.

Vonvendi is a recombinant von Willebrand factor previously only approved for on-demand and perioperative use in adults with VWD and routine prophylactic use in adults with severe Type 3 VWD receiving ...

Topline data were announced from a trial evaluating enlicitide in adults with hypercholesterolemia on a moderate or high intensity statin.

Adults with obesity prefer a primary care visit characterized by respectful treatment and listening, according to a study published online.

In patients with in-hospital silent graft occlusion after CABG, there is increased risk for angina-related rehospitalization and revascularization.

The FDA has accepted for review the NDA for ensitrelvir for the prevention of COVID-19 following exposure to an infected individual.

For women with myocardial infarction (MI), beta-blocker therapy is associated with worse outcomes, according to a study published online.

Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Topline data were announced from a trial evaluating vericiguat in patients with stable chronic heart failure and reduced ejection fraction.